Unicycive Therapeutics, Inc.
UNCY
$5.09
$0.061.09%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 7.64% | 37.31% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 20.18% | 16.79% | |||
| Operating Income | -20.18% | -16.79% | |||
| Income Before Tax | 86.57% | 12.58% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 86.57% | 12.58% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 86.57% | 12.58% | |||
| EBIT | -20.18% | -16.79% | |||
| EBITDA | -20.23% | -16.84% | |||
| EPS Basic | 88.07% | 21.64% | |||
| Normalized Basic EPS | 88.07% | 21.65% | |||
| EPS Diluted | 88.15% | 21.10% | |||
| Normalized Diluted EPS | 88.07% | 21.65% | |||
| Average Basic Shares Outstanding | 12.59% | 11.56% | |||
| Average Diluted Shares Outstanding | 12.59% | 11.56% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||